Southwest Chemical Dependency Program Dillon

Southwest Chemical Dependency Program Dillon is a SAMHSA-registered addiction-treatment facility located at Dillon, MT. The facility's programming is outpatient (Outpatient, Dual Dx), not residential. Patient-level evaluation of this facility should distinguish three considerations: state licensure status, voluntary accreditation (CARF or Joint Commission), and clinical-framework alignment with current ASAM Criteria — each of which is independently verifiable.

Care levels at Southwest Chemical Dependency Program Dillon

Southwest Chemical Dependency Program Dillon is an outpatient-focused program (Outpatient, Dual Dx) — patients live at home or in sober living and attend treatment sessions. This level of care is clinically appropriate for mild-to-moderate substance use disorder, or for patients stepping down from residential. Operational prerequisite for admission: documented clinical assessment establishing medical necessity for the specific level of care Southwest Chemical Dependency Program Dillon provides. The ASAM Criteria 4e framework is the benchmark standard for this assessment and is referenced in most major payer medical-necessity documents.

Insurance and payment

Southwest Chemical Dependency Program Dillon accepts both Medicaid and commercial insurance, which is the broadest payer profile and typically correlates with programs that operate at scale across the economic spectrum. The facility also accepts TRICARE or military benefits. Benefit verification should be obtained in writing prior to admission and should document: network contract status for the specific insurance product, prior authorization requirements and approved day-count, applicable cost-sharing structure, and out-of-network secondary coverage (where applicable). Proceeding on verbal VOB creates material risk of post-admission benefit dispute.

Before you call

Pre-admission due-diligence for Southwest Chemical Dependency Program Dillon: (1) ASAM 4e level-of-care documentation matching clinical assessment; (2) written Verification of Benefits specific to insurance product; (3) MAT policy documentation (particularly buprenorphine and methadone continuation protocols for opioid use disorder patients); (4) accreditation verification via CARF or Joint Commission provider-search tools; (5) state licensing status confirmed via MT behavioral-health regulator inspection records. If the clinical situation involves opioid use disorder, confirm explicitly whether Southwest Chemical Dependency Program Dillon offers medication-assisted treatment — buprenorphine, methadone, or naltrexone. Programs that do not are operating outside the current standard of care.